These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F; Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983 [TBL] [Abstract][Full Text] [Related]
24. Aromatase inhibitors for the treatment and prevention of breast cancer. Kalidas M; Brown P Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070 [TBL] [Abstract][Full Text] [Related]
25. Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient. Goldhirsch A Breast; 2013 Aug; 22 Suppl 2():S3-7. PubMed ID: 24074788 [TBL] [Abstract][Full Text] [Related]
26. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022 [TBL] [Abstract][Full Text] [Related]
27. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061 [TBL] [Abstract][Full Text] [Related]
30. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T; Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060 [TBL] [Abstract][Full Text] [Related]
31. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G; Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065 [TBL] [Abstract][Full Text] [Related]
32. The nature of tamoxifen action in the control of female breast cancer. Kodama M; Kodama T In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224 [TBL] [Abstract][Full Text] [Related]
33. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer. Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545 [TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy for breast cancer--results from the USA consensus conference. Abrams JS Breast Cancer; 2001; 8(4):298-304. PubMed ID: 11791121 [TBL] [Abstract][Full Text] [Related]
35. The influence of endocrine treatments for breast cancer on health-related quality of life. Buijs C; de Vries EG; Mourits MJ; Willemse PH Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425 [TBL] [Abstract][Full Text] [Related]
36. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer. Benson JR J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197 [No Abstract] [Full Text] [Related]
37. Endocrine therapy of breast cancer. Goldhirsch A; Colleoni M; Gelber RD Ann Oncol; 2002; 13 Suppl 4():61-8. PubMed ID: 12401668 [No Abstract] [Full Text] [Related]
38. Anti-tumor effects of letrozole. Miller WR; Anderson TJ; Dixon JM Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345 [TBL] [Abstract][Full Text] [Related]
39. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749 [TBL] [Abstract][Full Text] [Related]